Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Keros Therapeutics, Inc. (KROS)

Keros Therapeutics posts updated November 2026 corporate presentation

Neutral Impact 2 of 5 other Written later

Keros Therapeutics updated its corporate presentation for investor meetings and furnished it as Exhibit 99.1 to a Form 8-K filed November 5, 2026. The deck restates the company's pipeline, including the Takeda license for elritercept, which included a $200 million upfront payment, and timelines for rinvatercept trials in DMD and ALS.

Key points

  • Takeda paid Keros a $200 million upfront payment for global rights to elritercept, excluding mainland China, Hong Kong and Macau
  • Keros is eligible for milestone payments of over $1.1 billion under the Takeda agreement
  • Keros expects to report initial data from its Phase 2 DMD trial of rinvatercept in the first half of 2027
  • Keros plans to engage regulators on its ALS Phase 2 trial design in the second half of 2026

The filing

CompanyKeros Therapeutics, Inc. (KROS)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:11 PM ET
Accession number0001664710-26-000067

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.